Biogen Idec’s Facet takeover bid falls through
World News | December 18, 2009
PharmaTimes
Talks between Biogen Idec and Facet Biotech over an unsolicited $493 million takeover bid have fallen through after investors were not persuaded to tender a majority of shares.
It is understood Biogen Idec may increase it’s offer, which was originally condemned by Facet chief executive Faheem Hasnain as “inadequate and did not fairly value our company”. Meanwhile, Facet is believed to be pursuing other “appropriate opportunities”.
Some analysts have suggested Bristol-Myers Squibb as a possible suitor in takeover talks.
Click here to order a reprint of this news story.
Tags
Biogen Idec
Facet Biotech
Facet takeover
Bristol Myers squibb
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.